Jade Biosciences, Inc. Profit Breakdown
Profit breakdown shows how much each product earned: one column per product, one row per year or quarter. All amounts are the filed figures for that period.
- Jade Biosciences, Inc. operating income for the quarter ending 2026-06-30 was -$58.92M, a change of -$31.14M year-over-year.
- Jade Biosciences, Inc. operating income for the quarter ending 2026-03-31 was -$43.45M, a change of -$20.06M year-over-year.
- Jade Biosciences, Inc. operating income for the quarter ending 2025-12-31 was -$34.98M, a change of -$28.58M year-over-year.
- Jade Biosciences, Inc. operating income for the quarter ending 2025-09-30 was -$27.4M, a change of -$11.85M year-over-year.
- Jade Biosciences, Inc. operating income for fiscal 2025 was -$113.54M, a change of -$38.95M from fiscal 2024.
- Jade Biosciences, Inc. operating income for fiscal 2024 was -$74.6M, a change of $6.81M from fiscal 2023.
- Jade Biosciences, Inc. operating income for fiscal 2023 was -$81.41M, a change of -$28.17M from fiscal 2022.
- Jade Biosciences, Inc. operating income for fiscal 2022 was -$53.24M, a change of -$30.22M from fiscal 2021.
- Available history
- 2020-03-31 to 2026-06-30
- Data captured
Profit by product
Jade Biosciences, Inc. did not file profit by product.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |